WO2011097273A8 - Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine - Google Patents

Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine Download PDF

Info

Publication number
WO2011097273A8
WO2011097273A8 PCT/US2011/023434 US2011023434W WO2011097273A8 WO 2011097273 A8 WO2011097273 A8 WO 2011097273A8 US 2011023434 W US2011023434 W US 2011023434W WO 2011097273 A8 WO2011097273 A8 WO 2011097273A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cysteine
acetyl
compositions
alcoholic fatty
Prior art date
Application number
PCT/US2011/023434
Other languages
French (fr)
Other versions
WO2011097273A1 (en
Inventor
James Hoffman
Connye Kuratko
Edward B. Nelson
Alan Ryan
Norman Salem
Original Assignee
Martek Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corporation filed Critical Martek Biosciences Corporation
Publication of WO2011097273A1 publication Critical patent/WO2011097273A1/en
Publication of WO2011097273A8 publication Critical patent/WO2011097273A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention is related to methods and compositions for treating non-alcoholic fatty liver disease (NAFLD), and methods of enhancing liver health and/or liver function, in a subject in need thereof, the methods comprising administering to the subject about 200 mg to about 12 g of docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA), and an effective amount of N-acetyl L-cysteine (NAC).
PCT/US2011/023434 2010-02-02 2011-02-02 Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine WO2011097273A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30082210P 2010-02-02 2010-02-02
US61/300,822 2010-02-02
US30595210P 2010-02-18 2010-02-18
US61/305,952 2010-02-18
US36734910P 2010-07-23 2010-07-23
US61/367,349 2010-07-23

Publications (2)

Publication Number Publication Date
WO2011097273A1 WO2011097273A1 (en) 2011-08-11
WO2011097273A8 true WO2011097273A8 (en) 2011-10-20

Family

ID=44355749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/023434 WO2011097273A1 (en) 2010-02-02 2011-02-02 Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine

Country Status (1)

Country Link
WO (1) WO2011097273A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
EP2701697B1 (en) 2011-04-26 2020-03-25 Retrotope, Inc. Oxidative retinal diseases
EP3730135A1 (en) 2011-04-26 2020-10-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
EP2701695B1 (en) 2011-04-26 2019-04-03 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
US10154978B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
WO2013115636A1 (en) * 2012-02-02 2013-08-08 Universiti Sains Malaysia Composition for the treatment and/or prevention of fatty liver disease
BR112017012811A2 (en) * 2014-12-15 2018-04-10 Dsm Ip Assets B.V. new treatment for non-alcoholic fatty liver disease
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
JOP20190146A1 (en) * 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
CU20200012A7 (en) 2017-08-14 2021-02-04 Axcella Health Inc AMINO ACID COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASE
US20210212936A1 (en) * 2018-06-01 2021-07-15 Baxter International Inc. Parenteral nutrition formulation
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP2022505215A (en) * 2018-10-18 2022-01-14 ディーエス バイオファーマ リミテッド DGLA and / or 15-HETRE for treating inflammatory, fibrotic, and proliferative conditions
CN109464454B (en) * 2018-11-29 2021-07-02 天津中医药大学 Application of brown algae oligosaccharide in preparation of medicine for treating or preventing liver injury
WO2021028737A1 (en) 2019-08-13 2021-02-18 Team Foods Colombia S.A. Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld)
CN110846346B (en) * 2019-11-26 2021-06-22 瞿瀚鹏 Microbial oil rich in Sn-2 DHA, and preparation method and application thereof
EP4107163A1 (en) 2020-02-21 2022-12-28 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016833A (en) * 1999-06-15 2002-03-06 뉴트리-로직스, 인크. Nutrient Formulations for Disease Reduction, and Related Treatment and Component Screening Methods
US20090182022A1 (en) * 2006-01-05 2009-07-16 Reliant Pharmaceuticals Treatment of Fatty Liver
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids

Also Published As

Publication number Publication date
WO2011097273A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
WO2008018043A3 (en) Methods of improving bone health and muscle health
GB2459809A (en) Fatty acid formulations and methods of use thereof
NZ600167A (en) Concentrated therapeutic phospholipid compositions
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
CO6470839A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF EMPLOYMENT
NZ757815A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2007058538A3 (en) Composition with docosapentaenoic acid
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
GT201200056A (en) CONJUGATES OF NIACINA AND FATTY ACIDS AND THEIR USES
MY163520A (en) Metabolic imprinting effects of specifically designed lipid component
MX2012005744A (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases.
EA200970238A1 (en) APPLICATION OF OILS WITH DPA (n-6) IN CHILDREN'S FOOD
BRPI0418921A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a
PH12017500074A1 (en) Nutritional compositions containing oil blends and uses thereof
NZ609527A (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
RU2013146517A (en) COMPOSITIONS AND METHODS SUITABLE FOR FACILITATION OF AGE DISEASES
MX2014000770A (en) Fatty acid compositions.
BR112014019927A8 (en) nutritional formula, method of preparing said formula prior to ingestion by an individual, use of said formula, device for preparing it and container
PH12018500090A1 (en) Nutritional compositions and methods for promoting cognitive development
MX2013010076A (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE.
WO2007103160A3 (en) Stearidonic acid for improving cardiovascular health
BRPI0512528A (en) use of polyunsaturated fatty acids, nutritional composition, and use of a composition
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740286

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740286

Country of ref document: EP

Kind code of ref document: A2